Table 4 Changes from baseline in apoCII and apoCIII
Study 565 | Study 566a | Study 1003 | |||||
|---|---|---|---|---|---|---|---|
Placebo | Alirocumab 150 mg Q2W | Placebo + ATV 80 mg | Alirocumab 150 mg Q2W + ATV 10 mg | Alirocumab 150 mg Q2W + ATV 80 mg | Placebo | Alirocumab 150 mg Q2W | |
n = 30 | n = 28 | n = 27 | n = 26 | n = 29 | n = 14 | n = 16 | |
ApoCII | |||||||
Baseline | 4.7 (2.1) | 5.0 (2.1) | 5.0 (1.8) | 4.9 (2.1) | 5.3 (2.0) | 4.8 (2.3) | 4.4 (1.9) |
Post- treatmentb | 5.3 (2.8) | 3.8 (1.4) | 4.3 (1.8) | 4.2 (1.4) | 3.7 (1.8) | 4.7 (2.0) | 3.7 (1.0) |
% change from baseline | 12.7 (32.6) | −18.2 (28.3)** | −7.6 (36.3) | −8.8 (23.0) | −27.8 (20.6)* | 1.6 (15.5) | −9.4 (28.1) |
ApoCIII | |||||||
Baseline | 11.0 (4.0) | 10.5 (3.2) | 11.0 (4.6) | 11.2 (4.1) | 11.5 (4.5) | 12.3 (4.5) | 11.5 (4.7) |
Post- treatmentb | 12.2 (6.1) | 8.6 (2.5) | 10.0 (3.5) | 9.8 (2.7) | 8.9 (3.1) | 11.6 (3.2) | 9.4 (2.3) |
% change from baseline | 12.1 (37.5) | −16.1 (20.1)** | −2.0 (34.1) | −9.4 (19.5) | −19.1 (17.7)* | −1.8 (19.3) | −14.5 (19.7) |